Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

Completed · Phase 2

Conditions studied: High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma

In brief

Phase 2, open-label study of nab-sirolimus in patients with recurrent high grade glioma following prior therapy and patients with newly diagnosed glioblastoma. nab-Sirolimus was administered as single agent or in combination therapies.

Key facts

Study ID

NCT03463265

Run by

Aadi Bioscience, Inc.

People needed

62

Starts

2018-08-01

Expected to finish

2022-08-26

Last updated by the study team

2023-11-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• St. Joseph Heritage Healthcare — Fullerton, California, United States
• Hoag Memorial Hospital Presbyterian — Newport Beach, California, United States
• John Wayne Cancer Institute — Santa Monica, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.